EMA Recommends Granting a Marketing Authorisation for Aumolertinib By Ogkologos - January 8, 2026 378 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with EGFR-mutated NSCLC Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer February 20, 2024 Radiotherapy Can Be Safely Omitted in Older Women with Low-Risk, HR-positive... February 24, 2023 FDA Approves Sacituzumab Govitecan-hziy for HR-positive Advanced Breast Cancer February 15, 2023 24% of Breast Cancers Diagnosed Between Mammograms Could Have Been Detected... May 10, 2021 Load more HOT NEWS Foodie Fridays: Watermelon Salad Efficacy of Tivozanib Monotherapy in the Post-ICI Setting Among Patients with... EMA Recommends Granting a Marketing Authorisation for Zolbetuximab FDA Approves Nivolumab for Adjuvant Treatment of Urothelial Carcinoma
